Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 21 resultados

SMA-TB: A novel Stratified Medicine Algorithm to predict treatment responses to host directed therapy in TB... LIONEX GMBH participó en un H2020: H2020-SC1-BHC-2018-2020 Tuberculosis (TB) is a chronic, life-threatening infectious disease which poses a tremendous challenge for physicians, researchers and Healt...
2019-12-06 - 2024-12-31 | Financiado

BactiVax: anti Bacterial Innovative Vaccine Training Network. LIONEX GMBH participó en un H2020: H2020-MSCA-ITN-2019 BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in...
2019-08-19 - 2024-03-31 | Financiado

EMI-TB: Eliciting Mucosal Immunity to Tuberculosis LIONEX GMBH participó en un H2020: H2020-PHC-2014-2015 Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium...
2014-11-26 - 2019-06-30 | Financiado

RAPP-ID: Development of RApid Point-of-Care test Platforms for Infectious Diseases LIONEX GMBH participó en un FP6: RAPP-ID (Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hos...
2011-04-01 - 2016-09-30 | Financiado

DEMO-NOPERSIST: Demonstration of NOPERSIST results leading to novel validated diagnostic tests for active human and... LIONEX GMBH tramitó un FP7: Tuberculosis (TB) in humans and bovine TB in farm animals are global health problems of immense social and economic importance. Human TB:...
Financiado

NOPERSIST: Novel strategies for the prevention and control of persistent infections LIONEX GMBH tramitó un FP7: Persistent infections such as HIV, tuberculosis´(TB) in humans and para-tuberculosis (ParaTB)-, mycoplasma- and Haemophilus-infections in fa...
Financiado

SYSTEMTB: Systems biology of Mycobacterium tuberculosis LIONEX GMBH participó en un FP7: Tuberculosis (TB) is a re-emerging global health threat caused by Mycobacterium tuberculosis (Mtb). One third of the world's population is i...
Financiado

HOMITB: Host and microbial molecular dissection of pathogenesis and immunity in tuberculosis LIONEX GMBH participó en un FP7: Tuberculosis (TB) is a leading public health problem. About half of the 10% of Mycobacterium tuberculosis-infected individuals develop overt...
Financiado

RAPP-ID: Development of RApid Point of Care test Platforms for Infectious Diseases LIONEX GMBH participó en un FP7: RAPP-ID (Development of RApid Point-of-Care test Platforms for Infectious Diseases) will develop a Point-of-Care Test (POCT) for rapid (hosp...
Financiado

Pocket: Development of a low cost point of care test for Tuberculosis detection LIONEX GMBH participó en un FP7: Pocket will develop a novel point-of-care (PoC) urine test for the detection of tuberculosis (TB), achieving at the same time a low cost (5...
Financiado

EURIPRED: European Research Infrastructures for Poverty Related Diseases HIV/AIDS, Tuberculosis (TB) and Malaria alone account for more than six million deaths worldwide every year. Despite substantial efforts mad...
Financiado

TRANSVAC: European Network of Vaccine Development and Research LIONEX GMBH participó en un FP7: The TRANSVAC infrastructure will accelerate the pharmaceutical and clinical development of promising vaccine candidates by bringing the gap...
Financiado

AEROPATH: The identification characterisation and exploitation of novel Gram negative drug targets LIONEX GMBH participó en un FP7: An ambitious long-term programme of multidisciplinary research with two closely linked objectives is proposed to support antimicrobial drug...
Financiado

IP4PLASMA: Industrial innovations based on EU intellectual property assets in the field of atmospheric plasma... LIONEX GMBH participó en un FP7: The IP4Plasma project aims to bridge the gap between IPR protected laboratory-scale innovations in the field of atmospheric pressure plasma...
Financiado

BURULIVAC: Identification and development of vaccine candidates for Buruli Ulcer Disease LIONEX GMBH participó en un FP7: Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is a neglected bacterial infection of the poor in remote rural areas, mostly a...
Financiado

DIPROMON: Multimodular biomarker analysis workflow for diagnosis prognosis and monitoring of drug treatment... LIONEX GMBH participó en un FP7: "With the advent of Omics technologies capable of profiling substantial fractions of molecular entities from the genome down to the metabolo...
Financiado

FAST-XDR-DETECT: Development of a two approach plate system for the fast and simultaneous detection of MDR and XDR M.... LIONEX GMBH participó en un FP7: Tuberculosis (TB) continues being a leading cause of death due to a single infectious disease agent. The HIV/AIDS pandemic and the emergence...
Financiado

RESPOC: Fast cost effective user friendly point of care POC instrument for detection of respiratory path... LIONEX GMBH participó en un FP7: Molecular techniques such as PCR (polymerase chain reaction) are becoming increasingly used for the detection of respiratory pathogens, due...
Financiado